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Abstract
Brain tumours are masses of abnormal cells that can grow in an uncontrolled
way in the brain. There are different types of malignant brain tumours.
Gliomas are malignant brain tumours that grow from glial cells and are
identified as astrocytoma, oligodendroglioma, and ependymoma. We study
a mathematical model that describes glia-neuron interaction, glioma, and
chemotherapeutic agent. In this work, we consider drug sensitive and resis-
tant glioma cells. We show that continuous and pulsed chemotherapy can
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kill glioma cells with a minimal loss of neurons.
Keywords: brain, tumour, chemotherapy, drug resistance, glia-neuron
interaction
1. Introduction
Tumour cells are abnormal cells that are classified into benign and ma-
lignant. The benign tumours do not invade the normal tissue, while the
malignant tumour invade and can spread around the body [1]. The malig-
nant tumours are cancerous tumours and they have a growth rate much faster
than normal cells [2, 3]. Cancer is one of the main causes of death worldwide
and many treatments have been developed, such as chemotherapy, surgery,
and radiation therapy [4].
Thermodynamic analysis related to the energy management of cancer cells
was developed by Lucia and Grisolia [5]. In 2013, Lucia [6] proposed the use
of engineering thermodynamic approach on data collected from brain and
breast tumours, as well as, therapy based on entropy generation approach
[7]. One example of this type of therapy is the application of electromag-
netic fields [8, 9]. Recently, Bergandi et al. [10] showed the efect of very
low frequency electromagnetic field in the cancer growth and developed a
thermodynamic model to obtain the type of frequency. Mathematical mod-
elling of tumour growth has been used to understand different aspects of
cancer [11, 12, 13].Pinho et al. [14] analysed a mathematical model of cancer
treatment by chemotherapy agent taking metastasis into account. Borges
et al. [15] used a model to study tumour growth under treatment by con-
tinuous and pulsed chemotherapy. Nani and Freedman [16] studied cancer
immunotherapy through models that incorporate tumor-immune interaction
[17].
One of the most common type of malignant brain tumour is the glioma
that starts in the glial cells [18]. The glial cells provide neuronal support and
protection [19]. In the literature, it is possible to find different brain tumour
models. Partial [20] and ordinary [21] differential equations have been used
to simulate the dynamic behaviour related to the glioma growth.
Drug resistance in cancer is a major problem in chemotherapy treatment
[22], due to the ability of cancerous cells to develop resistance to chemother-
apeutic agents [23]. Nass and Efferth [24] studied drug targets and resistance
mechanisms in myeloma. Recently, He et al. [25] reported mechanisms re-
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lated to drug-resistant ovarian-cancer cells. A mathematical modelling of
therapy, inducing cancer drug resistance, was analysed by Sun et al. [26].
We propose a model with glioma drug resistance by adding a new differential
equation in the model proposed by Iarosz et al. [27] for gliomas with glia-
neuron interactions and chemotherapy treatment. The authors computed
the values of the infusion of chemotherapy agents in which the glioma is
suppressed and a minimum number of neurons is lost, without neurogenesis.
In this work, the novelty is that we consider glioma drug resistance. In this
way, our model has glia-neuron interactions, resistant and sensitive gliomas,
as well as chemotherapy treatment. The tumour treatment occurs through
continuous or pulsed chemotherapy. In the continuous chemotherapy, the
neuronal lifespan depends on the infusion of chemotherapy agent rate and
the mutation rate from drug-sensitive to drug-resistant cells. With regard
to the pulsed chemotherapy, we show that the chemotherapy cycle and the
time interval of the drug application play important roles in the treatment.
This paper is organised as follows: in Section 2 we introduce the math-
ematical model, Section 3 presents our results for continuous and pulsed
chemotherapy, and in the last Section we draw our conclusions.
2. Brain tumour model with drug resistance
We include drug resistance in the Iarosz model [27]. Figure 1 displays
a schematic representation with the interactions considered in the modified
model. The sensitive and resistant glioma cells have logistic growth, as well
as they attack the glial cells and do not attack the neurons. The glial cells
interact with the neurons, attack the glioma cells, and have logistic growth.
The chemotherapy agent is a predator that attack the glioma cells, glial cells,
and neurons. Due to the chemotherapy, the sensitive glioma cells convert to
resistant glioma cells through mutations.



















































= Φ− ζQ(t), (5)
where G is the glial cells concentration (kg.m−3), S is the drug sensitive
glioma cells concentration (kg.m−3), R is the resistant drug glioma cells con-
centration (kg.m−3), N is the neurons concentration (kg.m−3), Q is the che-




0, x ≤ 0,
1, x > 0.
(6)
Table 1 describes the values of the parameters taken from the referenced
literature. In Eqs. (2) and (3), the third term is related to the change from
sensitive to resistant glioma cells. In Eq. (4), the first term is associated
with the decay of the neuronal population due to the glial cells death.
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The normalised model is given by
dg(t)
dt






















= Φ− ζQ(t), (11)
where g(t) = G(t)
C1
, s(t) = S(t)
C2
, r(t) = R
C2
, n(t) = N(t)
C3
, β1 = ΨGC2, β2 = ΨSC1,
β3 = ΨRC1, α = ψC1, ai =
Ai
Ci
, and ii =
Ii
Ci
(i = 1, 2, 3). The values of the
parameters are given in Table 2.





−1 Proliferation rate [28, 29]
PR 0.002 and 0.006 day
−1
ψ 0− 0.02 Loss influences [28]
I1, I3 2.4× 10
−5 m2(mg·day)−1 Interaction
I2 2.4× 10
−2 m2(mg·day)−1 coefficients [28, 30]
Φ 0− 200 mg(m2.day)−1 Chemotherapy [31, 32]
ζ 0.2 day−1 Absorption rate [15]
u 0− 1 Mutation rate
A1, A2, A3 510 kg.m




−6 day−1 coefficients [28]
C1, C2, C3 510 kg.m
−3 Carrying capacity [33]
The equilibria points, which are physiologically feasible, E(g, s, r, n,Q)
of the model are obtained through ġ(t) = 0, ṡ(t) = 0, ṙ(t) = 0, ṅ(t) = 0, and
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β2, β3 1.8× 10
−3 day−1
α 0− 10
a1, a2, a3 1




Q̇(t) = 0. First, we analyse the local stability for an undesirable equilibrium,
where this equilibrium is given by E0(0, 0, 0, 0,Φζ

























5 = −ζ. (16)
We identify the stability of the equilibrium through the sign of the real part
of each eigenvalue. In a hyperbolic equilibrium, if the real part of each
eigenvalue is strictly negative, then the equilibrium is locally asymptotically
stable, and if positive, then the equilibrium is unstable. In order to ensure
the stability of E0(0, 0, 0,Φζ









where these results are obtained by means of λ
(0)
1 < 0 and λ
(0)
2 < 0. The val-





5 are negative. However, the eigenvalue λ
(0)
3 is positive. There-
fore, the equilibrium E0(0, 0, 0, 0,Φζ
−1) is unstable, due to the fact that the
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resistant drug glioma cells are not affected by the chemotherapeutic agent.
It is possible to find a stable equilibrium E1(0, 0, r
∗, 0,Φζ−1) for r∗ = 1. The
eigenvalues of the Jacobian matrix are
λ
(1)





















5 = −ζ. (23)
In order to ensure the stability of E1(0, 0, r





where these results are obtained through λ
(0)







4 , and λ
(0)
5 are negative because the values of the normalised parameters
are positive. We consider a1 = 1, PG = 0.0068, β1 = 0.018, i1 = 4.7 × 10
−8,
and ζ = 0.2 (table 2). With these values, we obtain that E1 is linearly
asymptotically stable for Φ > −47659, 57. Therefore, when the chemother-
apeutic agent kills all glial cells (g) and drug sensitive glioma cells (s), the
normalised resistant drug glioma cells concentration is r = 1.
We also consider the equilibrium E2(g, 0, 0, n, Q) that represents the com-
plete elimination of drug sensitive glioma cells and resistant drug glioma cells,
in addition, the glial and neuron cells are preserved. This equilibrium is ob-









Φ− ζQ = 0, (27)
for n = 0 and Q = Φζ−1. Thus, the equilibrium E2(g, 0, 0, n, Q) is given by
E2(g, 0, 0, 0,Φζ
−1), meaning that all neurons are also eliminated. Equation
7
(25) can be rewritten as




Using the parameters of Table 1 and 2, g has a real, positive and non null

























5 = −ζ. (33)
For a1 = 1, λ
(2)
1 is negative in Equation (29) when




From Equation (28), it is obtained i1Φ
ζPG
= 1− g2, consequently
(1− g2)− 2g2 − 2g3 < (1− g2), (35)
therefore λ
(2)
1 < 0 if g > 0. λ
(2)
2 is negative for combinations of u and Φ,
for example: i) u = 0 and Φ > 43.41, ii) u = 0.001 and Φ > 39.15, and iii)




5 are negative. However, λ
(0)
3
is positive if PR > β3. Using the parameters from Tables 1 and 2, we obtain
β3 = 0.0018 and PR ≥ 0.002. For realistic parameters, the equilibrium E2
is unstable, due to the fact that the proliferation rate of the resistant drug
glioma cells is larger than the normalized competition coefficient between
glioma and resistant drug glioma cells.
The equilibrium E2, which is related to the elimination of all glioma cells,
is unstable. In this case, all neurons are also eliminated, showing that it is
impossible find a cure for glioma in the drug resistant case. For this reason,




In continuous chemotherapy, the anticancer drugs are administered with-
out pauses [34]. Continuous infusion, followed by radiotherapy, was used as a
treatment for malignant tumour. Many researchers reported that this combi-
nation can improve the tumours regression [35, 36]. We consider continuous

































Figure 2: (Colour online) Time evolution of (a) glial cells concentration g(t), (b) neurons
concentration n(t), (c) drug sensitive glioma cells concentration s(t), and (d) resistant drug
glioma cells concentration r(t) for Φ = 200, PR = 0.002, and there mutation rate u = 0
(blue line), u = 10−3 (red line), and u = 10−2 (black line). The green and orange vertical
dashed lines correspond to 360 days (12 months) and 540 days (18 months), respectively.
We consider g(0) = 1, n(0) = 1, s(0) = 0.01, r(0) = 0, and Q(0) = 0.
Figure 2 shows the time evolution of normalised (a) glial cells concen-
tration g(t), (b) neurons concentration n(t), (c) drug sensitive glioma cells
concentration s(t), and (d) resistant drug glioma cells concentration r(t). We
consider Φ = 200, PR = 0.002, u = 0 (blue line), u = 10
−3 (red line), and
u = 10−2 (black line). The chemotherapeutic agent kills the glial cells, neu-
rons, and sensitive glioma cells. For u = 0, there is not resistant glioma, and
as a consequence the malignant tumour is suppressed. However, n decreases
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from 1 to 0.981 for t = 360 days (12 months) (green vertical dashed line) and
to 0.977 for t = 540 days (18 months) (orange vertical dashed line). The glial
cells are killed by glioma and chemotherapy, but they exhibit logistic growth
and saturation. For u = 10−3, n goes to 0.980 and 0.976 for 360 and 540
days, respectively. Considering u = 10−2, we observe n = 0.971 for t = 360
days, and n = 0.966 for t = 540 days. In addition, the sensitive glioma cells
are absent for t greater than approximately 150 days.
In Fig. 3, we see the time τ to achieve a neuron concentration n = 0.9
as a function of Φ. For u = 0 (blue line) and Φ = 200, τ is equal to 3926
days, while τ is much less for u = 10−3 (red line) and u = 10−2 (black line).
We obtain τ equal to 3672 and 2910 days for u equal to 10−3 and 10−2,
respectively. Then, it is possible to verify that u has an important effect on
τ .














Figure 3: (Colour online) τ as a function of Φ for PR = 0.002, u = 0 (blue line), u = 10
−3
(red line), and u = 10−2 (black line).
We also calculate τ by varying Φ and u, as shown in Fig. 4. The colour bar
represents the values of τ . In our simulations, the blue region corresponds to
τ greater than 700 days. In the orange, black and red regions, the τ values are
for about 650, 500 and 350 days, respectively. The τ values less than 300 days
are in the green region. Figure 4(a), for PR = 0.002, is separated into four
regions denoted by I, II, III, and IV. In the region I, we have s(t) < 0.01 and
r(t) < 0.01, namely when n = 0.9 both sensitive and resistant gliomas have
a concentration less than the initial glioma concentration. Region II, s(t) <
0.01 and r(t) > 0.01, shows that only the sensitive glioma is suppressed. The
sensitive glioma grows in region III, s(t) > 0.01 and r(t) < 0.01. In the region
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IV, both sensitive and resistant glioma have a concentration greater than the
initial glioma concentration, s(t) > 0.01 and r(t) > 0.01. For PR = 0.006


































Figure 4: (Colour online) Time (τ) to achieve the concentration (n = 0.9) (colour bar) as
a function of Φ× u for (a) PR = 0.002 and (b) PR = 0.006.
3.2. Pulsed chemotherapy
Pulsed chemotherapy is the use of intermittent schedules of chemother-
apeutic agents to treat diseases [37]. Researchers have been carrying out
various treatment types with different protocols to eliminate cancerous cells.
In literature, it is possible to find results based on theoretical studies [38, 39]
and experiments [40]. Our intermittent schedule is illustrated in Fig. 5(a),
where ∆t1 and ∆t2 correspond to the time intervals with (days on) and with-
out (days off) chemotherapy, respectively. Figure 5(b) displays the temporal
evolution of q(t). We observe an exponential growth of drug concentration












































Figure 5: (a) Intermittent schedule of the pulsed chemotherapy, where ∆t1 and ∆t2 are
the time intervals with (days on) and without (days off) chemotherapy, respectively. (b)
Temporal evolution of drug concentration q(t).
Figure 6 shows (a) g(t), (b) n(t), (c) s(t), and (d) r(t) for ∆t1 = 7 days
with Φ = 200 and ∆t2 = 21 days. We consider PR = 0.002, u = 0 (blue
line), u = 10−3 (red line), and u = 10−2 (black line). At t = 360 days
(green vertical dashed line), we find n = 0.964, n = 0.963, and n = 0.956
for u = 0, u = 10−3, and u = 10−2 respectively. When t = 540 days,
n = 0.963 for u = 0, n = 0.962 for u = 10−2, and n = 0.951 for u = 10−2.
In this intermittent schedule, the n values are less than the results found
considering the continuous chemotherapy.
There are many types of treatment schedules. With this in mind, we vary
the number of days on and off to analyse the effects of the drug resistance
on different chemotherapy protocols. Figure 7 exhibits τ (colour bar) as a
function of ∆t2 × ∆t1. In Fig. 7(a), we verify the existence of the four
regions, where the region IV is very small and it is between the regions II
and III. For u = 10−2, there are only the regions I and II, as shown in Fig.
7(b). The region I is larger for u = 10−3 (Fig. 7(a)) than for u = 10−2 (Fig.
7(b)). Therefore, the region I decreases and the region II increases when u






































Figure 6: (Colour online) Time evolution of (a) g(t), (b) n(t), (c) s(t), and (d) r(t) for
∆t1 = 7 days with Φ = 200 and ∆t2 = 21 days with Φ = 0, PR = 0.002, u = 0 (blue line),
u = 10−3 (red line), and u = 10−2 (black line). The green and orange vertical dashed
lines correspond to 360 and 540 days, respectively.
both sensitive and resistant glioma cells decreases.
4. Conclusions
There are many different types of brain tumours. The treatments depend
on the tumour characteristics. One of the most common malignant tumours
in the brain is the glioma. This tumour begins in the glial cells and affects the
support for the neurons. Due to this fact, without support and protection,
the number of neurons decreases.
We extend the mathematical model of brain tumour growth proposed
by Iarosz et al. [27]. The Iarosz model describes glia-neuron interaction
and chemotherapy treatment. In this work, we modify the model separating
the equation of the glioma cells into two equations. The new equations
correspond to sensitive and resistant glioma cells.
We consider continuous and pulsed chemotherapy to destroy glioma cells
without harming a large number of neurons. With regard to the continuous






































Figure 7: (Colour online) τ (colour bar) as a function of ∆t2 × ∆t1 for PR = 0.002, (a)
u = 10−3 and (b) u = 10−2.
rate u from sensitive to resistant glioma cells increases. The τ values depend
on Φ and u. For small PR values, we find values in the parameter space
Φ × u (region I) where the continuous chemotherapy kills both sensitive
and resitant gliomas. In the pulsed chemotherapy, the region of the best
treatment according to days on and off decreases for larger u values.
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